Relay Therapeutics, Inc. (RLAY) — Analyst outlook / Analyst consensus target is. Based on 15 analyst ratings, the consensus is bullish — 1 Strong Buy, 14 Buy.
The consensus price target is $16.33 (low: $13.00, high: $22.00), representing an upside of 10.7% from the current price $14.75.
Analysts estimate Earnings Per Share (EPS) of $-2.51 and revenue of $0.02B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.36 vs est $-2.51 (beat +5.9%). 2025: actual $-1.61 vs est $-1.73 (beat +7%). Analyst accuracy: 93%.
RLAY Stock — 12-Month Price Forecast
$16.33
▲ +10.71% Upside
Average Price Target
Based on 15 Wall Street analysts offering 12-month price targets for Relay Therapeutics, Inc., the average price target is $16.33, with a high forecast of $22.00, and a low forecast of $13.00.
The average price target represents a +10.71% change from the last price of $14.75.
Highest Price Target
$22.00
Average Price Target
$16.33
Lowest Price Target
$13.00
RLAY Analyst Ratings
Buy
Based on 15 analysts giving stock ratings to Relay Therapeutics, Inc. in the past 3 months
EPS Estimates — RLAY
93%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.36
vs Est –$2.51
▲ 6.3% off
2025
Actual –$1.61
vs Est –$1.73
▲ 7.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — RLAY
66%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.010B
vs Est $0.015B
▼ 50.7% off
2025
Actual $0.015B
vs Est $0.013B
▲ 16.6% off
Revenue Trend
Moderate revenue growth trend. Analysts expect stable revenue going forward.
